

New claims 3 through 8 are added as follows:

~~A2~~

3. A transgenic mouse whose somatic and germ cells comprise a disruption in an endogenous H2-Oa gene, wherein disruption is generated by targeted replacement with a non-functional H2-Oa gene, and wherein said disruption results in said mouse having an increase in the amount of serum IgG1 at 10 months of age as compared to wild-type H2-Oa mice.
4. The mouse of claim 3, wherein said mouse is fertile and transmits the non-functional H2-Oa gene to its offspring.
5. The mouse of claim 3, wherein the non-functional H2-Oa gene has been introduced into an ancestor of the mouse at an embryonic stage by microinjection of altered embryonic stem cells into mouse blastocysts.
6. A method for producing a transgenic mouse whose somatic and germ cells comprise a disruption in an endogenous H2-Oa gene, wherein said disruption is generated by targeted replacement with a non-functional H2-Oa gene, said method comprising:
 - a) introducing a H2-Oa gene targeting construct comprising a selectable marker sequence into a mouse embryonic stem cell;
 - b) introducing said mouse embryonic stem cell into a mouse blastocyst;
 - c) transplanting said blastocyst into a recipient mouse;
 - d) allowing said blastocyst to develop to term;
 - e) identifying a transgenic mouse whose genome comprises a disruption of an endogenous H2-Oa gene in at least one allele; and

f) breeding the mouse of step (e) to obtain a transgenic mouse whose genome comprises a homozygous disruption of the endogenous H2-Oa gene,
wherein said disruption results in said mouse having an increase in the amount of serum IgG1 by ten months of age as compared to wild-type H2-Oa mice.

AZ
Cont'd

7. The method of claim 6 wherein the introducing of step (a) is by electroporation or microinjection.
8. An isolated cell line derived from the transgenic mouse of claim 3.

Respectfully submitted,

John W. Wallen, III
Reg. No. 35,402
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(858) 784 - 3239
DATE: 28 February 2002